Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet
Aclarion (Nasdaq: ACON, ACONW) will participate in the 38th Annual ROTH Conference March 22-24, 2026, in Dana Point, CA to meet institutional investors and analysts.
Rhea-AI Summary
Aclarion (Nasdaq: ACON, ACONW) will participate in the 38th Annual ROTH Conference March 22-24, 2026, in Dana Point, CA to meet institutional investors and analysts.
CEO Brent Ness will hold one-on-one meetings to discuss progress advancing Nociscan, the company’s MR spectroscopy platform, and emphasize a strong balance sheet, no debt, and plans to expand adoption in the UK and US.
Positive
- None.
Negative
- None.
Details
News Market Reaction – ACON
On Mar 17, the day this news came out, ACON closed 0.62% above the previous close.
Data tracked by StockTitan Argus for the Mar 17 session.
Key Figures
- CLARITY trial size
- 300 patients
- Target enrollment for CLARITY trial, internal readout expected end Q3 2026
- Recent financing
- $10.4 million
- Common-stock-only financing closed Jan 12, 2026
- Cash balance
- $21.6 million
- Cash as of Jan 12, 2026 after financing; debt-free balance sheet
- Share price in financing
- $5.18 per share
- Price for Jan 2026 common-stock-only financing
- Fully diluted shares
- 2,882,371 shares
- Fully diluted share count from 2026 shareholder letter
- Scan volume growth
- +69% YoY
- 2025 annual Nociscan scan volume vs 2024
- Q4 2025 volume growth
- +114% YoY
- Q4 2025 Nociscan scan volume vs prior-year quarter
- Q3 2025 net loss
- $1.71 million
- Net loss for Q3 2025 from Form 10-Q
Historical Context
-
CEO investor meetings at LSI USA 2026 to discuss Nociscan progress.
-
2026 priorities, CLARITY trial timeline, cash runway and capital structure update.
-
Agreement with Source Healthcare to integrate Nociscan and generate real-world data.
-
Common-stock financing strengthening cash to $21.6M and extending runway to 2028.
-
2026 outlook, strong scan growth and cash of $12.0M supporting operations into H1 2027.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
biomarkers medical
augmented intelligence technical
mr spectroscopy medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BROOMFIELD, Colo., March 17, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that it will participate in the 38th Annual ROTH Conference, March 22-24, 2026, in Dana Point, CA.
During the conference, CEO Brent Ness will engage in one-on-one meetings with institutional investors and analysts to discuss the company’s progress advancing Nociscan, the company’s proprietary MR spectroscopy platform designed to help physicians identify painful discs in patients suffering from chronic low back pain.
“We look forward to engaging with the investment community at ROTH to share the progress we are making and the important catalysts ahead for Aclarion,” said Brent Ness, CEO of Aclarion. “With a strong balance sheet, no debt, and a focused strategy to expand adoption of Nociscan in both the UK and US, we believe we are well positioned to execute on the significant opportunity ahead.”
To schedule a 1-on-1 meeting with Mr. Ness during the ROTH conference, please email: ksmith@pcgadvisory.com.
For more News from Aclarion, please visit: Latest News
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email: info@aclarion.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the enrollment of patients in our ongoing clinical trial, an initial interim data readout is expected to be internally available at the end of Q3, the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contacts:
Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.